Outcomes of Pharmaceutical Care in Patients with Pulmonary Tuberculosis at Somdejprasangkharach XVII Hospital, Suphanburi
Article Sidebar
Main Article Content
Abstract
Objective: To compare treatment outcomes between patients with pulmonary tuberculosis who received pharmaceutical care and those who didn’t. Method: The study was prospective study at Somdejprasangkharach XVII Hospital during April 2016 to November 2016. One hundred and two patients receiving pharmaceutical care (study group) consisted of 49 patients in intensive phase and 53 in continuing phase. Seventy nine of those not receiving pharmaceutical care (control group) were collected the data retrospectively from their medical record. The study employed interview to collect information on pharmaceutical care and drug related problems. Quality of life before and after the provision of pharmaceutical care was measured with the brief version of World Health Organization instrument (WHOQOL-BREF or WHOQOL-26). Results: The proportion of subjects in experimental group having negative sputum at the end of the second month was statistically significant higher than that in control group (p <0.05). Among 115 drug related problems identified in the experimental group, 92 were resolved (80%). The most prevalent drug-related problem was adverse drug reactions (54 problems or 47%). Conclusions: Pharmaceutical care in patients with pulmonary tuberculosis improved treatment outcomes, increased medication adherence and resolved drug related problems, leading to a better quality of life.
Article Details
ผลการวิจัยและความคิดเห็นที่ปรากฏในบทความถือเป็นความคิดเห็นและอยู่ในความรับผิดชอบของผู้นิพนธ์ มิใช่ความเห็นหรือความรับผิดชอบของกองบรรณาธิการ หรือคณะเภสัชศาสตร์ มหาวิทยาลัยสงขลานครินทร์ ทั้งนี้ไม่รวมความผิดพลาดอันเกิดจากการพิมพ์ บทความที่ได้รับการเผยแพร่โดยวารสารเภสัชกรรมไทยถือเป็นสิทธิ์ของวารสารฯ
References
2. Marinker MA. From compliance to concordance: achieving shared goals in medicine taking. Br Med J 1997; 314: 717-18.
3 American Thoracic Society and Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med. 2000;161(suppl): 221-47.
4. Wells BG, Dipiro JT, Schwinghammer TL, Hamilton CW. Pharmacotherapy handbook, 3rd ed Singapore : McGraw-Hill; 2006.
5. Blumberg HM, Buram WJ, Chaisson RE, Daley CL Etkind SC, Friedman LN, et al. American Thoracic Society/Centers for Disease Control and Prevention /Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med. 2003; 167: 603-62.
6. Forget EJ, Menzies D. Adverse reactions to first-line antituberculosis drugs. Expert Opin Drug Saf 2006; 5: 231-49.
7. Jasmer RM. Short-course rifampin and pyrazina- mide compared with isoniazid for latent tuberculo sis infection: a multicenter clinical trial. Ann Intern Med 2002;137:640-78.
8. Ungo JR, Jones D, Ashkin D, Hollender ES, Bernstein D, Albanese AP, Pitchenik AE. Antituber culosis drug-induced hepatotoxicity: the role of hepatitis C virus and the human immunodeficiency virus. Crit Care Med. 1998; 8:1871-6.
9. Ana TC, Mariana M, Sara F, Paulo CR. Incidence and risk factors of major toxicity associated to first-line anti-tuberculosis drugs for latent and active tuberculosis during a period of 10 years. Rev Port Pneumol 2014;21:145-9.
10. Sudeep N, Anuradha L, Olugbenga O, Richard E. Errors in the treatment of tuberculosis in Baltimore. Chest 2000; 111: 734-7.
11. Supongpattanakit S. Drug related problems in tuberculosis patients at Tuberculosis Control Center 10 Chiang Mai. [independent study]. Chiang Mai: Chiangmai University; 2000.
12. Somsong W. Adherence to tuberculosis treatment and conversion rate in HIV infected tuberculosis patients [master thesis]. Bangkok: Mahidol Univer-sity; 2002.
13. Yew WW. Therapeutic drug monitoring in antituber culosis chemotherapy. Ther Drug Monit. 1998; 20: 469-72.
14. Putlerpong C, Santimaleeworlakun W, MontakarntI kun P, Pattarachayakun S, Sonthisombut P. Phar- macist initiative for patient tuberculosis. Bangkok: Association of Hospital Pharmacy (Thailand); 2012.
15. Pummangura C, Tunyasandsuk K. Philosophy of pharmaceutical care practice. Bangkok: Newthaimit; 2000.
16. Hepler CD, Strand LM. Opportunities and response bilities in pharmaceutical care. Am J Hosp Pharm. 1990;4 7: 533-54.
17. Mahutnirunkun S. The program for mental health survey in the area in 2002 [online]. 2002 [cited Aug 1, 2015]. Available from: www.dmh.go.th/test/down load/files/whoqol.pdf.
18. World Health Organization. WHOQOL-BREF: intro duction, administration, scoring and generic version of the assessment, field trial version [online]. 1996 [cited Aug 17, 2015]. Available from: www.who.int/ mental_health/media/en/76.pdf.
19. Trevittaya P. Concepts of quality of life [editorial]. Bulletin of Chiangmai Associated Medical Sciences 2016; 49: 171-181.
20. Srisatidnarakul B. Methodology in nursing research 3rd ed. Bangkok: U&I Inter Media; 2004.
21. Kawwongwarn J, Singsiwanon P. Sample size determination in clinical trials. In: Pitisuttitum P, Pichiansontorn C, editors. Textbook of clinical research. Bangkok: Faculty of Tropical Medicine, Mahidol University; 2011.
22. World Health Organization. Treatment of Tubercu losis: guidelines for national programmes 4th ed. [online]. 2009 [cited May 19, 2015]. Available from: www.who.int/tb/publications/tb_treatmentguidelines/en/.
23. Pefura-Yone EW, Kengne AP, Kuaban C. Non-conversion of sputum culture among patients with smear positive pulmonary tuberculosis in Came roon: a prospective cohort study. BMC Infect Dis 2014;14:138.
24. Tassanawijit P. Effect of pharmaceutical care in tuberculosis patient at Ngao hospital [master thesis] . Chiangmai: Chaingmai University; 2003.
25. Boonjarat S. Effect of Pharmacist involvement on drug related problems in a tuberculosis clinic: assessment of patient outcomes and doctors responses [master thesis]. Khon Kaen: Khon Kaen University; 2002.
26. Muhammad A, Syed AS, Sulaiman AAS, Muham mad KS, Heng CL, Zaheer UDB. Impact of tubercu losis treatment on health-related quality of life of pulmonary tuberculosis patients: a follow-up study. BMC Infect Dis. 2014; 12: 1-11.
